FDA warns patients to stop using six lots of compounded injections

The FDA has posted a nationwide recall of six lots of compounded injectable products from Centric Compounding LLC after the company reported elevated endotoxin levels in the glutathione active pharmaceutical ingredient used to make them.

Patients and clinics should check their vials now. Anyone with a matching lot number should stop using the product, discard it and contact a health care provider about symptoms or other problems after use.

The FDA published the recall notice on September 13, 2026. Centric announced the recall on September 11, and the company’s recall release is dated September 9. The notice describes the action as a voluntary company recall posted by the FDA as a public service.

Six lots are included

The recall covers 30 mL multidose vials of three compounded products distributed nationwide through home delivery and prescribers:

• Glutathione 200 mg/mL: lot 062326:B, beyond-use date August 7, 2026; lot 070826:A, beyond-use date August 22, 2026; and lot 072726:D, beyond-use date September 25, 2026.
• Myer’s Cocktail: lot 070226:D, beyond-use date August 16, 2026; and lot 072126:A, beyond-use date September 4, 2026.
• Tri-Immune Boost: lot 071626:B, beyond-use date August 30, 2026.

The recall is limited to those six listed lots. It does not mean every vial or every product made by Centric Compounding is affected.

Why the recall matters

According to the FDA notice, elevated endotoxin levels in injectable products could cause serious reactions, including fever, hypotension, inflammatory reactions, anaphylactic shock and death.

Centric reported receiving nine reports involving fever, chills, chest pain, nausea or vomiting, headache and/or malaise. The notice lists those as reports received by the company; it does not establish that the products caused each reported symptom.

What patients and clinics should do

Check the lot number printed on the vial against the six recalled lots. Do not use a vial with a matching lot number, even if it looks normal or its beyond-use date has not passed.

Discard an affected vial and contact the prescriber or another health care provider if symptoms or other problems occurred after use. Anyone experiencing a possible serious reaction should seek urgent medical attention or emergency services.

Patients and clinics can contact Centric Compounding about recall questions or replacement arrangements. Suspected adverse reactions and product-quality problems can also be reported through the FDA’s MedWatch program.

What to watch next

Patients and clinics should watch for additional lot numbers, updated company instructions or further information from the FDA. Until then, the immediate step is to compare any Centric Compounding vial with the six recalled lot numbers and avoid using a matching vial.

Sources

• FDA MedWatch reporting program
• Houston Chronicle report on the Centric Compounding recall

Look for updates to this story

Related News

• FDA tells hospitals to inspect certain infant breathing circuits
• FDA Classifies Luna G3 Recall After Firmware Could Stop Therapy
• South Bronx Legionnaires’ Cluster Prompts Cleanup of 10 Towers
• Fifth Circuit weighs Louisiana bid to restrict telehealth access to mifepristone